Table 1.

Fallopian tube related model systems

Model system	Genetic alterations	BRCA related?	Precursor lesions	Reference
Ex-vivo
Epithelial 2D culture system	None	No	N/A	[27]
3D culture of fallopian tube secretory cells	None	No	N/A	[28]
Transformed cell lines
Transformed fallopian tube secretory cells (viral oncogenes)	hTERT + SV40 Large T-Ag + SV40 Small T-Ag +H-RASV12/c-Myc	No	Immortalized cells using hTERT+SV40 Large T-Ag + SV40 Small T-Ag	[29]
Transformed fallopian tube secretory cells (no viral oncogenes)	hTERT + P53 shRNA+ CDK4R24C (targeting Rb)+ PP2A B56γ shRNA + c-Myc	No	Immortalized cells using hTERT + P53 shRNA+ CDK4R24C	[29]
Transformed fallopian tube secretory cells (viral oncogenes)	hTERT + SV40 Large T-Ag +HRAS+cMYC	No (BRCA1 accumulation was observed)	None	[30]
Genetically engineered mouse models
AmhrII driven in fallopian tube mesenchymal cells	PTEN + DICER double knock out	No	None	[34]
OVGP-1 driven model	SV40 Large T-Ag	No	P53 signature and sTIC	[35]
PAX8 driven model	BRCA1 or BRCA2 deletion + P53 deletion or mutation +PTEN deletion	Yes	sTIC	[36]
OSE hilum model	Conditional knockout of P53 and RB in mouse OSE hilum (OSE and fallopian tube junction)	No	Cells transplanted intraperitoneally to recipient immune-deficient mice form HGSC.	[21]
Patient derived xenografts
Ovarian, fallopian tube, and primary peritoneal cancer engrafted in SCID mice	Representative of patient spectrum of genetic alterations	No	No	[43]
HGSC engrafted in NSG mice	Representative of patient spectrum of genetic alterations. All with mutated P53.	7 out of 10 samples	No	[42]